NKTR NEKTAR THERAPEUTICS

Nasdaq Pharmaceutical Preparations DE CIK: 0000906709
AI RATING
STRONG_SELL
88% Confidence

Investment Thesis

NKTR is in severe financial distress with revenue collapsing 43.9% YoY to only $10.9M while burning $44.3M in operating cash annually. Operating margins of -359.6% and net margins of -413.4% indicate a fundamentally broken business model with minimal profitability at the gross level (5.7% margin). Despite adequate short-term liquidity ($149.6M cash), the company faces an unsustainable 3-4 year cash runway at current burn rates without significant operational turnaround.

Strengths

  • + Strong liquidity position with $149.6M cash providing near-term runway
  • + Low leverage ratio of 0.23x Debt/Equity provides financial flexibility
  • + Solid stockholders equity base of $576.2M from accumulated investment

Risks

  • ! Catastrophic revenue decline of 43.9% YoY signals severe business deterioration
  • ! Negative operating cash flow of $44.3M annually with unsustainable burn rate
  • ! Extreme unprofitability with -359.6% operating margin and 5.7% gross margin indicating core business model failure
  • ! Cash runway of only 3-4 years at current burn rate without profitability inflection
  • ! EPS deterioration (-$1.82) despite net losses narrowing, indicating worsening per-share economics

Key Metrics to Watch

Financial Metrics

Revenue
10.9M
Net Income
-44.9M
EPS (Diluted)
$-1.82
Free Cash Flow
-44.3M
Total Assets
763.3M
Cash
149.6M

Profitability Ratios

Gross Margin 5.7%
Operating Margin -359.6%
Net Margin -413.4%
ROE -7.8%
ROA -5.9%
FCF Margin -408.0%

Balance Sheet & Liquidity

Current Ratio
10.21x
Quick Ratio
10.21x
Debt/Equity
0.23x
Debt/Assets
24.5%
Interest Coverage
N/A
Long-term Debt
133.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-16T09:44:16.078160 | Data as of: 2026-03-31 | Powered by Claude AI